Brain nanotargeted [131I] I-Rolapitant as a model for brain imaging: Intranasal formulation, radiolabelling, biodistribution, and comparative study
- 25 June 2023
- journal article
- research article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 86
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?Cancers, 2013
- Rolapitant (SCH 619734): A potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferretsPharmacology Biochemistry and Behavior, 2012
- Synthesis and preclinical pharmacological evaluation of 99mTc‐TEDP as a novel bone imaging agentJournal of Labelled Compounds and Radiopharmaceuticals, 2011
- Synthesis and biological evaluation of 125I-nebivolol as a potential cardioselective agent for imaging β1-adrenoceptorsJournal of Radioanalytical and Nuclear Chemistry, 2011
- Niosomal encapsulation of the antitubercular drug, pyrazinamideDrug Development and Industrial Pharmacy, 2011
- Strategy for effective brain drug deliveryEuropean Journal of Pharmaceutical Sciences, 2010
- Quantum Dots Bearing Lectin-Functionalized Nanoparticles as a Platform for In Vivo Brain ImagingBioconjugate Chemistry, 2008
- Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targetingJournal of Drug Targeting, 2005
- Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitantBiological Psychiatry, 2004
- Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain BarrierJournal of Drug Targeting, 2002